230 related articles for article (PubMed ID: 19621985)
1. Safety and tolerability of cyclosporin a in severe traumatic brain injury patients: results from a prospective randomized trial.
Mazzeo AT; Brophy GM; Gilman CB; Alves OL; Robles JR; Hayes RL; Povlishock JT; Bullock MR
J Neurotrauma; 2009 Dec; 26(12):2195-206. PubMed ID: 19621985
[TBL] [Abstract][Full Text] [Related]
2. Brain metabolic and hemodynamic effects of cyclosporin A after human severe traumatic brain injury: a microdialysis study.
Mazzeo AT; Alves OL; Gilman CB; Hayes RL; Tolias C; Niki Kunene K; Ross Bullock M
Acta Neurochir (Wien); 2008 Oct; 150(10):1019-31; discussion 1031. PubMed ID: 18781275
[TBL] [Abstract][Full Text] [Related]
3. Dosing and safety of cyclosporine in patients with severe brain injury.
Hatton J; Rosbolt B; Empey P; Kryscio R; Young B
J Neurosurg; 2008 Oct; 109(4):699-707. PubMed ID: 18826358
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporin A disposition following acute traumatic brain injury.
Empey PE; McNamara PJ; Young B; Rosbolt MB; Hatton J
J Neurotrauma; 2006 Jan; 23(1):109-16. PubMed ID: 16430377
[TBL] [Abstract][Full Text] [Related]
5. Exposure of cyclosporin A in whole blood, cerebral spinal fluid, and brain extracellular fluid dialysate in adults with traumatic brain injury.
Brophy GM; Mazzeo AT; Brar S; Alves OL; Bunnell K; Gilman C; Karnes T; Hayes RL; Bullock R
J Neurotrauma; 2013 Sep; 30(17):1484-9. PubMed ID: 23540442
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine A for neuroprotection: establishing dosing guidelines for safe and effective use.
Cook AM; Whitlow J; Hatton J; Young B
Expert Opin Drug Saf; 2009 Jul; 8(4):411-9. PubMed ID: 19548859
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine--results at six months after transplantation.
Eisen HJ; Hobbs RE; Davis SF; Laufer G; Mancini DM; Renlund DG; Valantine H; Ventura H; Vachiery JL; Bourge RC; Canver CC; Carrier M; Costanzo MR; Copeland J; Dureau G; Frazier OH; Dorent R; Hauptman PJ; Kells C; Master R; Michaud JL; Paradis I; Smith A; Vanhaecke J; Mueller EA
Transplantation; 1999 Sep; 68(5):663-71. PubMed ID: 10507486
[TBL] [Abstract][Full Text] [Related]
8. Oral cyclosporine A in neonatal swines for transplantation studies.
Pan H; Gazarian A; Buff S; Solla F; Gagnieu MC; Leveneur O; Watrelot-Virieux D; Morisset S; Sobh M; Michallet MC; Roger T; Dubernard JM; Michallet M
Immunopharmacol Immunotoxicol; 2015 Feb; 37(1):19-25. PubMed ID: 25358107
[TBL] [Abstract][Full Text] [Related]
9. Copenhagen Head Injury Ciclosporin Study: A Phase IIa Safety, Pharmacokinetics, and Biomarker Study of Ciclosporin in Severe Traumatic Brain Injury Patients.
Kelsen J; Karlsson M; Hansson MJ; Yang Z; Fischer W; Hugerth M; Nordström CH; Åstrand R; Keep MF; Kilbaugh T; Wang KKW; Møller K; Juhler M; Elmér E
J Neurotrauma; 2019 Dec; 36(23):3253-3263. PubMed ID: 31210099
[TBL] [Abstract][Full Text] [Related]
10. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial.
Xiao G; Wei J; Yan W; Wang W; Lu Z
Crit Care; 2008; 12(2):R61. PubMed ID: 18447940
[TBL] [Abstract][Full Text] [Related]
11. Pilot study to determine the hemodynamic safety and feasibility of magnesium sulfate infusion in children with severe traumatic brain injury.
Natale JE; Guerguerian AM; Joseph JG; McCarter R; Shao C; Slomine B; Christensen J; Johnston MV; Shaffner DH
Pediatr Crit Care Med; 2007 Jan; 8(1):1-9. PubMed ID: 17251875
[TBL] [Abstract][Full Text] [Related]
12. Statistical analysis plan for the Erythropoietin in Traumatic Brain Injury trial: a randomised controlled trial of erythropoietin versus placebo in moderate and severe traumatic brain injury.
Presneill J; Little L; Nichol A; French C; Cooper DJ; Haddad S; Duranteau J; Huet O; Skrifvars M; Arabi Y; Bellomo R; ;
Trials; 2014 Dec; 15():501. PubMed ID: 25528574
[TBL] [Abstract][Full Text] [Related]
13. The protective effect of cyclosporin A upon N-acetylaspartate and mitochondrial dysfunction following experimental diffuse traumatic brain injury.
Signoretti S; Marmarou A; Tavazzi B; Dunbar J; Amorini AM; Lazzarino G; Vagnozzi R
J Neurotrauma; 2004 Sep; 21(9):1154-67. PubMed ID: 15453986
[TBL] [Abstract][Full Text] [Related]
14. Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: results of a multi-center, randomized, placebo-controlled trial. American Brain Injury Consortium Study Group.
Marmarou A; Nichols J; Burgess J; Newell D; Troha J; Burnham D; Pitts L
J Neurotrauma; 1999 Jun; 16(6):431-44. PubMed ID: 10391361
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of changing from cyclosporine C0 to C2 monitoring in stable recipients following renal transplantation: a prospective cohort study.
Zhang Y; Zhang XD; Wang Y
Transplant Proc; 2011 Dec; 43(10):3697-701. PubMed ID: 22172829
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporin A preserves mitochondrial function after traumatic brain injury in the immature rat and piglet.
Kilbaugh TJ; Bhandare S; Lorom DH; Saraswati M; Robertson CL; Margulies SS
J Neurotrauma; 2011 May; 28(5):763-74. PubMed ID: 21250918
[TBL] [Abstract][Full Text] [Related]
17. Post-injury administration of the mitochondrial permeability transition pore inhibitor, NIM811, is neuroprotective and improves cognition after traumatic brain injury in rats.
Readnower RD; Pandya JD; McEwen ML; Pauly JR; Springer JE; Sullivan PG
J Neurotrauma; 2011 Sep; 28(9):1845-53. PubMed ID: 21875332
[TBL] [Abstract][Full Text] [Related]
18. The citicoline brain injury treatment (COBRIT) trial: design and methods.
Zafonte R; Friedewald WT; Lee SM; Levin B; Diaz-Arrastia R; Ansel B; Eisenberg H; Timmons SD; Temkin N; Novack T; Ricker J; Merchant R; Jallo J
J Neurotrauma; 2009 Dec; 26(12):2207-16. PubMed ID: 19803786
[TBL] [Abstract][Full Text] [Related]
19. Severe human traumatic brain injury, but not cyclosporin a treatment, depresses activated T lymphocytes early after injury.
Mazzeo AT; Kunene NK; Gilman CB; Hamm RJ; Hafez N; Bullock MR
J Neurotrauma; 2006 Jun; 23(6):962-75. PubMed ID: 16774480
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
Schädeli F; Marti HP; Frey FJ; Uehlinger DE
Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
